TETRACAINE HYDROCHLORIDE solution/ drops

Tetracaine Hydrochloride by

Drug Labeling and Warnings

Tetracaine Hydrochloride by is a Prescription medication manufactured, distributed, or labeled by Paragon BioTeck, Inc., Bausch & Lomb Incorporated. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% is indicated for procedures requiring

    a rapid and short-acting topical ophthalmic anesthetic.

  • 2 DOSAGE AND ADMINISTRATION

    One drop topically in the eye(s) as needed.

  • 3 DOSAGE FORMS AND STRENGTHS

    Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% is a clear, colorless, ophthalmic

    solution containing 0.5% w/v tetracaine hydrochloride equivalent to tetracaine 0.44% w/v.

  • 4 CONTRAINDICATIONS

    Tetracaine Hydrochloride Ophthalmic Solution, USP, 0.5% should not be used in patients with a

    history of hypersensitivity to any component of this preparation.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Corneal Injury with Intracameral Use

    Not for injection or intraocular use. Do not use intracamerally because use of Tetracaine

    Hydrochloride Ophthalmic Solution USP, 0.5% may lead to damage of the corneal endothelial

    cells.

    5.2 Corneal Toxicity

    Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial

    defects which may progress to permanent corneal damage.

    5.3 Corneal Injury due to Insensitivity

    Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental

    injuries can occur due to insensitivity of the eye.

  • 6 ADVERSE REACTIONS

    The following serious ocular adverse reactions are described elsewhere in the labeling:

    • Corneal Injury with Intracameral Use [See Warnings and Precautions (5.1)]
    • Corneal Toxicity [See Warnings and Precautions (5.2)]
    • Corneal Injury due to Insensitivity [See Warnings and Precautions (5.3)]

    The following adverse reactions have been identified following use of Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliable estimate their frequency or establish a causal relationship to drug exposure.

    Ocular Adverse Reactions

    Transient stinging, burning, and conjunctival redness, eye irritation, eye pain, ocular discomfort.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic

    Solution USP, 0.5% in pregnant women. Animal developmental and reproductive toxicity studies

    with tetracaine hydrochloride have not been reported in the published literature.

    8.2 Lactation

    Risk Summary

    There are no data to assess whether Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% is

    excreted in human milk or to assess its effects on milk production/excretion. The developmental

    and health benefits of breastfeeding should be considered along with the mother’s clinical need

    for Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% and any potential adverse effects

    on the breastfed child from Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5%.

    8.3 Females and Males of Reproductive Potential

    No human data on the effect of Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% on

    fertility are available.

    8.4 Pediatric Use

    Safety of Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% in the pediatric population

    has been demonstrated in clinical trials. Efficacy of Tetracaine Hydrochloride Ophthalmic

    Solution USP, 0.5% for use in pediatric patients has been extrapolated from adequate and well

    controlled clinical trials in the adult population.

    8.5 Geriatric Use

    No overall differences in safety or effectiveness of Tetracaine Hydrochloride Ophthalmic

    Solution USP, 0.5% have been observed between elderly and younger patients.

  • 10 OVERDOSAGE

    Prolonged use of a topical ocular anesthetic including Tetracaine Hydrochloride Ophthalmic

    Solution USP, 0.5% may produce permanent corneal opacification and ulceration with

    accompanying visual loss.

  • 11 DESCRIPTION

    Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% is a sterile, clear, colorless, topical

    local anesthetic for ophthalmic use containing tetracaine hydrochloride as the active

    pharmaceutical ingredient.

    Tetracaine hydrochloride is chemically designated as benzoic acid, 4-(butylamino)-,

    2-(dimethylamino) ethyl ester, monohydrochloride. Its chemical formula is C15H24N2O2

    HCl and it is represented by the chemical structure:

    chemstructure.jpg

    Tetracaine hydrochloride is a fine, white, crystalline, odorless powder with a molecular weight of

    300.82

    Active ingredient: tetracaine hydrochloride 0.5% w/v (equivalent to 0.44% w/v tetracaine)

    Preservative: chlorobutanol 0.4%

    Inactive ingredients: boric acid, potassium chloride, edetate disodium, water for injection USP.

    Sodium hydroxide and/or hydrochloric acid may be added to adjust pH (3.7 – 6.0)

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal

    impulses thereby affecting local anesthesia.

    12.3 Pharmacokinetics

    The systemic exposure to tetracaine following topical ocular administration of Tetracaine

    Hydrochloride Ophthalmic Solution USP, 0.5% has not been studied. Tetracaine hydrochloride is

    metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the

    published literature. Long-term animal studies have not been conducted to evaluate the

    carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of

    tetracaine hydrochloride on fertility have not been reported in the published literature.

  • 14 CLINICAL STUDIES

    Topical administration of Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% results in

    localized temporary anesthesia. The maximum effect is achieved within 10–20 seconds after

    instillation, with efficacy lasting 10–20 minutes. Duration of effect can be extended with

    repeated dosing. [See Warnings and Precautions (5.2) and Overdosage (10)].

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% is supplied as a sterile, aqueous,

    topical ophthalmic solution with a fill volume of 15 mL in a 15 mL low-density polyethylene

    plastic dropper bottle with a low-density polyethylene dropper tip and white polypropylene cap.

    NDC: 42702-170-15

    After opening, this product can be used until the expiration date stamped on the bottle.

    Storage: Store at 15°C to 25°C (59°F to 77°F). Protect from light. Do not use if solution

    contains crystals, cloudy, or discolored.

  • 17 PATIENT COUNSELING INFORMATION

    Eye Care Precaution

    Do not touch the dropper tip to any surface as this may contaminate the solution.

    Advise patients that, due to the effect of the anesthetic, their eyes will be insensitive for up to 20

    minutes and that care should be taken to avoid accidental injuries.

    Manufactured for:

    Paragon BioTeck, Inc.

    4640 SW Macadam Ave, Ste 80

    Portland, OR 97239

    Manufactured and Distributed by:

    Bausch & Lomb

    8500 Hidden River Pkwy

    Tampa, FL 33637

    Revised: March 2019

  • PACKAGE/LABEL PRINCIPAL DISPLAY PANEL- Carton 15 mL

    NDC 42702-170-15

    Paragon
    BioTeck, Inc.

    Tetracaine
    Hydrochloride

    Ophthalmic
    Solution, USP
    0.05%     (Sterile)

    Rx Only

    15 mL

    carton.jpg
  • INGREDIENTS AND APPEARANCE
    TETRACAINE HYDROCHLORIDE 
    tetracaine hydrochloride solution/ drops
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 42702-170
    Route of AdministrationOPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    TETRACAINE HYDROCHLORIDE (UNII: 5NF5D4OPCI) (TETRACAINE - UNII:0619F35CGV) TETRACAINE HYDROCHLORIDE5 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    CHLOROBUTANOL (UNII: HM4YQM8WRC)  
    BORIC ACID (UNII: R57ZHV85D4)  
    POTASSIUM CHLORIDE (UNII: 660YQ98I10)  
    EDETATE DISODIUM (UNII: 7FLD91C86K)  
    WATER (UNII: 059QF0KO0R)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 42702-170-151 in 1 CARTON03/12/2019
    115 mL in 1 BOTTLE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA21082103/12/2019
    Labeler - Paragon BioTeck, Inc. (078279037)
    Establishment
    NameAddressID/FEIBusiness Operations
    Bausch & Lomb Incorporated079587625MANUFACTURE(42702-170)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.